With the addition of CalPrem Roofing and CalPrem Solar, MARS now provides an expanded suite of services that enhances resiliency and long-term value for homebuilders and businesses.
Read More
With President Trump signaling openness to marijuana's medical benefits and 39 state attorneys general demanding a crackdown on unregulated hemp-derived THC, MMJ stands as the only federally compliant company prepared to deliver safe, pharmaceutical-grade cannabis treatments. As the nation moves toward a Federal Cannabis Reset, MMJ's FDA and DEA-aligned pathway offers the lawful, science-based solution America needs.
Read More
SMX (NASDAQ: SMX) and Goldstrom, a global leader in bullion banking, logistics, and trading, are to embed molecular-level traceability directly into gold and silver. The collaboration brings molecular verification to one of the world's oldest markets, creating a new foundation of transparency, accountability, and measurable proof across the precious metals industry.
Read MoreConference Call and Webcast set for Wednesday, November 12, 2025, at 4:15 PM Eastern time
"The Critical Minerals and ZEO Company"
~ Antimony, Cobalt, Tungsten, and Zeolite ~
Read More
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September
Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67th Annual American Society of Hematology (ASH) meeting in December
First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist
IND-enabling studies progressing as planned with triple-GLP/GIP/GCG agonists PN-477sc and PN-477o
Oral hepcidin development candidate expected to be nominated by year end
Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028
Read MoreResults of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37%
Read More
VSee explores collaboration with Philippine Tuberculosis Society and former VP Leni Robredo to expand digital health innovation for Naga City starting with maternal health and primary care
Read More89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials
Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors
Both molecules leverage Aptevo's unique use of the CRIS-7-derived CD3 binding domain, associated with favorable safety outcomes in the clinic; CD3 T-cell engager portfolio expanded to five
Company raises $18.7 million in the third quarter, $4.1 million since quarter end, extends cash runway into 4Q26
Read More